All Updates

All Updates

icon
Filter
Funding
Praxis Precision Medicines announces USD 59.1 million underwritten public offering
Precision Medicine
Jun 15, 2023
This week:
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
Product updates
Cognitive3D launches custom dashboards for XR analytics
Extended Reality
Oct 16, 2024
Funding
Mindtech raises GBP 4.4 million in funding to develop AI vision technology
Extended Reality
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Identity & Access Management
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Next-gen Cybersecurity
Oct 16, 2024
Precision Medicine

Precision Medicine

Jun 15, 2023

Praxis Precision Medicines announces USD 59.1 million underwritten public offering

Funding

  • Drug developer Praxis Precision Medicines announced an underwritten public offering of its common shares and pre-funded warrants. The offering includes 55.2 million common shares and pre-funded warrants to purchase up to 7.1 common shares. With a price set at USD 0.95 per share, the company aims to raise approximately USD 59.1 million.

  • Additionally, the company has also granted the underwriters a 30-day option to purchase an additional 9.3 million shares at the same price. The offering is expected to close on June 21, 2023, and the use of net proceeds was not disclosed.

  • The capital raised from this offering will likely support Praxis Precision Medicines' ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.

  • The public offering is being facilitated by Piper Sandler and Truist Securities, who are serving as the joint book-running managers for the offering. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.